347
Views
12
CrossRef citations to date
0
Altmetric
Original Articles

Serum glial fibrillary acidic protein (GFAP)-antibody in idiopathic intracranial hypertension

, , , , , , , , , , , , , ORCID Icon & ORCID Icon show all
Pages 775-779 | Received 14 Jan 2019, Accepted 02 Apr 2020, Published online: 28 Apr 2020

References

  • Wakerley BR, Tan MH, Ting EY. Idiopathic intracranial hypertension. Cephalalgia. 2015;35(3):248–261.
  • Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81(13):1159–1165.
  • Sinclair AJ, Ball AK, Burdon MA, et al. Exploring the pathogenesis of IIH: an inflammatory perspective. J Neuroimmunol. 2008;201–202:212–220.
  • Altıokka-Uzun G, Tüzün E, Ekizoğlu E, et al. Oligoclonal bands and increased cytokine levels in idiopathic intracranial hypertension. Cephalalgia. 2015;35(13):1153–1161.
  • Edwards LJ, Sharrack B, Ismail A, et al. Increased levels of interleukins 2 and 17 in the cerebrospinal fluid of patients with idiopathic intracranial hypertension. Am J Clin Exp Immunol. 2013;2(3):234–244.
  • Samancı B, Samancı Y, Tüzün E, et al. Evidence for potential involvement of pro-inflammatory adipokines in the pathogenesis of idiopathic intracranial hypertension. Cephalalgia. 2017;37(6):525–531.
  • Ekizoglu E, Içoz S, Tuzun E, et al. Aquaporin-4 antibodies are not present in patients with idiopathic intracranial hypertension. Cephalalgia. 2012;32(3):198–202.
  • Papadopoulos MC, Manley GT, Krishna S, et al. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J. 2004;18(11):1291–1293.
  • Dhungana S, Waters P, Ismail A, et al. Absence of aquaporin-4 antibodies in patients with idiopathic intracranial hypertension. J Neurol. 2010;257(7):1211–1212.
  • Altıokka-Uzun G, Erdağ E, Baykan B, et al. Glial and neuronal antibodies in patients with idiopathic intracranial hypertension. Neurol Sci. 2017;38(10):1817–1822.
  • Eide PK, Eidsvaag VA, Nagelhus EA, et al. Cortical astrogliosis and increased perivascular aquaporin-4 in idiopathic intracranial hypertension. Brain Res. 2016;1644:161–175.
  • Shan F, Long Y, Qiu W. Autoimmune glial fibrillary acidic protein astrocytopathy: a review of the literature. Front Immunol. 2018;9:2802.
  • Flanagan EP, Hinson SR, Lennon VA, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol. 2017;81(2):298–309.
  • Fang B, McKeon A, Hinson SR, et al. Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol. 2016;73(11):1297–1307.
  • Luessi F, Engel S, Spreer A, et al. GFAPα IgG-associated encephalitis upon daclizumab treatment of MS. Neurol Neuroimmunol Neuroinflamm. 2018;5(5):e481.
  • Chen JJ, Aksamit AJ, McKeon A, et al. Optic disc edema in glial fibrillary acidic protein autoantibody-positive meningoencephalitis. J Neuroophthalmol. 2018;38(3):276–281.
  • Iorio R, Damato V, Evoli A, et al. Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients. J Neurol Neurosurg Psychiatry. 2018;89(2):138–146.
  • Hergenroeder GW, Moore AN, Schmitt KM, et al. Identification of autoantibodies to glial fibrillary acidic protein in spinal cord injury patients. Neuroreport. 2016;27:90–93.
  • Wei P, Zhang W, Yang LS, et al. Serum GFAP autoantibody as an ELISA-detectable glioma marker. Tumor Biol. 2013;34(4):2283–2292.
  • Zoltewicz JS, Scharf D, Yang B, et al. Characterization of antibodies that detect human GFAP after traumatic brain injury. Biomark Insights. 2012;7:71–79.
  • Peng JH, Kung FT, Peng W, et al. Increased ALZ-50 immunoreactivity in CSF of pseudotumor cerebri patients. Ann Clin Lab Sci. 2006;36(2):151–156.
  • Vossler DG, Rostad SW, Haltiner AM, et al. Increased ictal discharge frequency and neocortex gliosis in lateral temporal lobe epilepsy. J Clin Neurophysiol. 2012;29(5):449–457.
  • Ebright MJ, Li SH, Reynolds E, et al. Unintended consequences of Mayo paraneoplastic evaluations. Neurology. 2018;91(22):e2057–e2066.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.